SPY is an exchange-traded fund (ETF) that aims to replicate the performance of the S&P 500 Index. The S&P 500 Index includes 500 of the largest publicly traded companies in the United States, representing a broad cross-section of the U.S. economy.
Metrics and analysis →GILD
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.
- Open
- —
- High
- —
- Low
- —
- Prev close
- 166.53
- Volume
- —
- Avg vol 10
- 5M
Today · Market closed · opens Mon 9:30 AM
GILD chart
Scroll or pinch to zoom, drag to pan, or use the buttons on the chart. About the price history
Technical analysis
Daily bars · last bar Nov 20, 2026 · close 167.58
No clear lean. 5 buy, 9 neutral and 4 sell across 18 signals. Stoch RSI sits in oversold territory. Trend strength is strong (ADX 30).
Trend
Momentum
Volatility
Volume
Leaning buy. The close is above 16 of 24 averages and below 8. Price is below the short-term averages (5 to 20) and above the long-term ones (50 to 200). SMA 50 is above SMA 200 (157.28 vs 142.31).
| Period | SMA | EMA | WMA | WEMA |
|---|---|---|---|---|
| 5 | 168.19 | 167.96 | 167.94 | 168.03 |
| 10 | 168.69 | 167.95 | 168.29 | 166.17 |
| 20 | 167.34 | 165.92 | 168.39 | 161.20 |
| 50 | 157.28 | 158.83 | 161.81 | 151.33 |
| 100 | 147.69 | 151.21 | 154.45 | 143.25 |
| 200 | 142.31 | 142.37 | 145.50 | 135.82 |
Green: the close is above that average. Red: below it.
From the bar before the last one. Nearest classic support is the pivot at 166.83. Nearest resistance is R1 at 168.86.
| Level | Classic | Fibonacci | Camarilla | Floor | Woodie | DeMark |
|---|---|---|---|---|---|---|
| R3 | 175.55 | 171.19 | 167.73 | 173.22 | 174.82 | — |
| R2 | 171.19 | 169.52 | 167.33 | 171.19 | 171.99 | — |
| R1 | 168.86 | 168.50 | 166.93 | 168.86 | 170.46 | 167.84 |
| Pivot | 166.83 | 166.83 | 166.83 | 166.83 | 167.63 | 166.32 |
| S1 | 164.50 | 165.16 | 166.13 | 164.50 | 166.10 | 163.48 |
| S2 | 162.47 | 164.14 | 165.73 | 162.47 | 163.27 | — |
| S3 | 158.11 | 162.47 | 165.33 | 160.14 | 161.74 | — |
Patterns that formed on the last 5 bars, newest first.
A small body with shadows longer than the body on both sides.
Neither side won the bar. On its own it says little; after a strong move it warns the move is tiring.
Two down candles, the second small and entirely inside the body of the first.
Selling is weakening; a turn up may follow.
A candle whose body completely covers the body of the one before it, in the opposite colour.
Sellers overwhelmed the previous session's buying; after an advance a turn down may follow.
An inside bar, then a break out of it one way that fails and reverses.
A false break lower trapped sellers; price may run up.
A doji sitting inside the body of the long candle before it.
The advance stalled abruptly; a turn down may follow.
A small body with shadows longer than the body on both sides.
Neither side won the bar. On its own it says little; after a strong move it warns the move is tiring.
A long down candle, then an up candle that opens below its low and closes more than halfway up its body.
Sellers were pushed back hard after a new low; a turn up may follow.
A candle with a long body and short shadows.
Sellers controlled the bar.
How candlestick references usually rate the pattern. It is not a success rate measured on this ticker. About candle patterns
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| Nov 20, 2026 | 168.28 | 170.24 | 165.80 | 167.58 | 8M | −0.70 |
| Nov 19, 2026 | 169.16 | 169.16 | 164.80 | 166.53 | 5M | −2.63 |
| Nov 18, 2026 | 168.78 | 170.63 | 167.36 | 168.98 | 5M | +0.20 |
| Nov 17, 2026 | 166.12 | 171.36 | 165.72 | 170.26 | 6M | +4.14 |
| Nov 16, 2026 | 171.04 | 171.80 | 166.75 | 167.58 | 5M | −3.46 |
| Nov 13, 2026 | 168.58 | 169.12 | 166.94 | 168.08 | 4M | −0.50 |
| Nov 12, 2026 | 171.15 | 171.70 | 167.93 | 167.95 | 4M | −3.20 |
| Nov 11, 2026 | 169.45 | 170.48 | 168.37 | 169.73 | 5M | +0.28 |
| Nov 10, 2026 | 170.15 | 171.15 | 167.61 | 170.87 | 5M | +0.72 |
| Nov 9, 2026 | 169.21 | 170.11 | 165.99 | 169.32 | 4M | +0.11 |
| Nov 6, 2026 | 164.11 | 169.06 | 164.00 | 166.89 | 6M | +2.78 |
| Nov 5, 2026 | 174.54 | 176.58 | 167.09 | 167.57 | 11M | −6.97 |
| Nov 4, 2026 | 171.89 | 175.41 | 168.84 | 174.48 | 10M | +2.59 |
| Nov 3, 2026 | 170.27 | 172.00 | 167.43 | 167.47 | 7M | −2.80 |
| Nov 2, 2026 | 169.85 | 172.61 | 166.38 | 170.33 | 9M | +0.48 |
| Oct 30, 2026 | 170.25 | 175.65 | 169.00 | 170.68 | 11M | +0.43 |
| Oct 29, 2026 | 162.89 | 165.70 | 160.86 | 165.61 | 8M | +2.72 |
| Oct 28, 2026 | 157.28 | 160.83 | 156.04 | 159.20 | 5M | +1.92 |
| Oct 27, 2026 | 156.05 | 159.28 | 155.76 | 159.08 | 5M | +3.03 |
| Oct 26, 2026 | 157.62 | 159.69 | 157.52 | 158.69 | 6M | +1.07 |
| Oct 23, 2026 | 156.47 | 157.65 | 155.76 | 156.04 | 6M | −0.43 |
| Oct 22, 2026 | 154.24 | 157.42 | 153.00 | 157.19 | 6M | +2.95 |
| Oct 21, 2026 | 154.73 | 155.42 | 151.71 | 153.57 | 6M | −1.16 |
| Oct 20, 2026 | 155.37 | 157.48 | 154.02 | 156.51 | 6M | +1.14 |
| Oct 19, 2026 | 155.39 | 157.24 | 152.92 | 153.07 | 7M | −2.32 |
| Oct 16, 2026 | 157.32 | 157.58 | 155.62 | 156.19 | 8M | −1.13 |
| Oct 15, 2026 | 156.39 | 160.51 | 156.02 | 157.37 | 8M | +0.98 |
| Oct 14, 2026 | 148.19 | 153.76 | 147.48 | 153.54 | 6M | +5.35 |
| Oct 13, 2026 | 151.16 | 151.16 | 147.26 | 147.92 | 6M | −3.24 |
| Oct 12, 2026 | 151.84 | 152.26 | 149.80 | 150.43 | 6M | −1.41 |
Performance
Daily returns for Jan 1, 2026 – Nov 22, 2026 (YTD). About the returns · About the risk figures
1 month return
5.88%
Change in value over the past month.
3 month return
13.42%
Change in value over the last three months.
Max drawdown
22.03%
Largest fall from a peak to the low that followed.
Standard deviation
27.92%
How far daily returns stray from their average, annualised.
Sharpe ratio
1.40
Return above the risk-free rate per unit of volatility.
Calmar ratio
1.78
Annualised return against the maximum drawdown.
GILD summary
Loading summary…
GILD, answered
How does Gilead support patient access to medications?
Gilead has programs in place to assist patients in accessing medications, including financial assistance and support services.
What is Gilead’s pipeline like?
Gilead has a robust pipeline of investigational therapies targeting various diseases, including multiple candidates in late-stage clinical trials.
How does Gilead Sciences ensure drug safety?
Gilead Sciences conducts extensive clinical trials and adheres to strict regulatory guidelines to ensure the safety and efficacy of its drugs.
What are Gilead’s recent acquisitions?
Gilead has made several strategic acquisitions to enhance its research capabilities and expand its product portfolio; check their investor reports for specifics.
Where is the headquarters of Gilead Sciences?
Gilead Sciences is headquartered in Foster City, California, USA.
How can I buy GILD stock?
You can buy GILD stock through a brokerage account or consult a financial advisor.
What diseases does Gilead Sciences focus on?
Gilead focuses on developing therapies for HIV, liver diseases, cancer, inflammatory diseases, and other serious conditions.
Does Gilead Sciences have a corporate responsibility program?
Yes, Gilead is committed to corporate responsibility, focusing on access to medicines, environmental sustainability, and community support.
Is GILD publicly traded?
Yes, Gilead Sciences is publicly traded on the NASDAQ under the ticker symbol GILD.
Does Gilead Sciences pay dividends?
Yes, Gilead Sciences pays dividends. Check their investor relations page for the latest information on dividend amounts.
GILD in the news
Top market assets
Discover our curated selection of top-performing exchange-traded funds (ETFs) that represent a diverse range of investment opportunities.
QQQ is an exchange-traded fund (ETF) that tracks the performance of the Nasdaq-100 Index. This index includes 100 of the largest non-financial companies listed on the Nasdaq Stock Market, primarily focusing on technology and innovation sectors.
Metrics and analysis →DIA is an exchange-traded fund (ETF) that aims to track the performance of the Dow Jones Industrial Average (DJIA). The DJIA is a stock market index consisting of 30 large, publicly traded companies in the United States, representing a broad range of industries.
Metrics and analysis →IWM is an exchange-traded fund (ETF) that seeks to track the performance of the Russell 2000 Index. The Russell 2000 Index measures the performance of the 2,000 smallest stocks in the Russell 3000 Index, representing a broad segment of small-cap U.S. companies.
Metrics and analysis →Advance Your GILD Trading Now
Experience the future of trading with OHLCX Platform. Our advanced system delivers in-depth analysis and insights for GILD, utilizing state-of-the-art technical tools and strategies. Elevate your trading approach instantly and see how we can elevate your trading results!
Disclaimers
The information displayed on this site is sourced from third-party providers and is believed to be reliable. OHLCX has not independently verified this data and does not guarantee its accuracy. Content is for educational and informational purposes only and is not financial or investment advice.
With any investment, your capital is at risk. Past performance is no guarantee of future results. Consult your provider's terms and privacy policies where applicable.
Prices, charts and every figure derived from them are delayed by at least 15 minutes and are provided for information only; we do not guarantee their accuracy or timeliness.
Securities products are: Not FDIC insured · Not bank guaranteed · May lose value
Trademarks and logos are the property of their respective owners and do not represent endorsements of any kind.